leisure time -WSS

leisure time

author：hotspot 2025-10-01 00:46:53 - browse：4473

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Biden tests positive for Covid

leisure time

WSS

HIV drugs protect against transmission, even in unprotected sex

Key House panel plots a new health care package

FDA's Pazdur wants cancer trials to range beyond China alone

Letters to First Opinion on caregivers, digital health, and more

Startup Neumora takes a novel depression drug to Phase 3

Change Healthcare can notify patients about the breach, HHS says

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Alkermes shareholders re

Ultragenyx gene therapy for rare liver ailment succeeds in late

Malaria cases in Florida and Texas: Here’s what you need to know

At Orexo, a ‘turning point’ for everything but digital health

The high cost of giving birth even with insurance

WHO calls for emergency meeting on new China virus, as cases spread

Hepatitis C has a cure — but many Americans still lack access to it

ASCO: AstraZeneca says CAR

As demand for Covid shots wanes, Moderna seeks its next success

ASCO: Palliative care found as helpful given virtually as in person

hotspot

In early work, researchers turn to CRISPR to treat Alzheimer's

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Cosmetics set for new safety regulation. Why the industry is on board

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Letters to First Opinion on caregivers, digital health, and more

Cord blood banking comes at a high cost to babies

hotspot

leisure time

focus

knowledge